抗流感病毒药物联合应用的研发及进展  

Research development and progress of anti-influenza drug combinations

作　　者：任永成 杨博元 王静[1] 岑山[1] REN Yong-cheng;YANG Bo-yuan;WANG Jing;CEN Shan(Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China;Shanghai Medical College,Fudan University,Shanghai 200032,China)

机构地区：[1]中国医学科学院、北京协和医学院医药生物技术研究所,北京100050 [2]复旦大学上海医学院,上海200032

出　　处：《药学学报》2025年第4期884-894,共11页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金面上项目(81971950);中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-038)。

摘　　要：人流感主要由甲型流感病毒和乙型流感病毒引起,是影响人类健康最严重的传染病之一。目前针对流感病毒的上市药物较少,且现有药物面临耐药性等问题。抗流感药物联用的开发与研究逐渐得到人们的重视。目前,在抗流感药物组合发现和药物效应评价等方面已经取得了一定进展。通过发现有效的联用药物可用于提高治疗效果,延迟或减少耐药性的发生,是实现老药新用的理想方法。本文对抗流感药物联用的评价方法和模型以及可用的数据资源和工具进行总结和介绍,并对当前抗流感药物联用研究的最新进展进行回顾和总结,以期为抗流感病毒药物联合应用的研发提供参考。Human influenza is mainly caused by influenza A virus and influenza B virus,and it is one of the most serious infectious diseases that pose a serious threat to human health.Currently,there are few marketed drugs for influenza viruses,and the existing drugs are faced with problems such as drug resistance.The development and research of combinations of anti-influenza drugs have gradually attracted people's attention.At present,certain progress has been made in aspects such as the discovery of anti-influenza drug combinations and the evaluation of drug effects.Discovering effective combination drugs is an ideal method for repurposing old drugs.That can be used to improve therapeutic effects and delay or reduce the occurrence of drug resistance.Herein,this article introduces the evaluation methods,models of combinations of anti-influenza drugs,as well as available data resources and tools,and summarizes the latest progress in the current research on combinations of anti-influenza drugs,with the aim of providing a reference for the research and development of the combined application of anti-influenza virus drugs.

关 键 词：流感病毒 药物效应 协同作用 评价模型 药物联合治疗 

分 类 号：R966[医药卫生—药理学]